Literature DB >> 3094774

Blood cyclosporin concentrations and renal allograft dysfunction.

D W Holt, J T Marsden, A Johnston, M Bewick, D H Taube.   

Abstract

Forty nine renal allograft recipients taking oral cyclosporin suffered 76 episodes of renal dysfunction within six months of transplantation. These episodes were diagnosed as graft rejection or cyclosporin induced nephrotoxicity on the basis of histological findings in allograft biopsy specimens and the response to treatment. Mean predose blood cyclosporin concentrations measured by radioimmunoassay during the week before the onset of renal dysfunction were significantly higher when the cause was cyclosporin toxicity rather than graft rejection (392 v 741 nmol/l (471 v 891 ng/ml). During this period there was a significant association between both the frequency of measurements above 666 nmol/l (800 ng/ml) and the diagnosis of toxicity and the frequency of measurements below 333 nmol/l (400 ng/ml) and the diagnosis of allograft rejection. Cyclosporin measurements made at the time of biopsy and reference to the highest or lowest concentrations measured during the week preceding biopsy were of less value in distinguishing between the two groups. Despite lacking specificity for the parent compound, the radioimmunoassay used produced results which were of clinical value in optimising cyclosporin treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094774      PMCID: PMC1341913          DOI: 10.1136/bmj.293.6554.1057

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  9 in total

1.  The United Kingdom Cyclosporin Quality Assessment Scheme.

Authors:  A Johnston; J T Marsden; D W Holt
Journal:  Ther Drug Monit       Date:  1986       Impact factor: 3.681

2.  Cyclosporine blood concentrations in the management of renal transplant recipients.

Authors:  M E Rogerson; J T Marsden; K E Reid; M Bewick; D W Holt
Journal:  Transplantation       Date:  1986-02       Impact factor: 4.939

3.  Cyclosporine-associated renal dysfunction in marrow transplant recipients.

Authors:  G C Yee; M S Kennedy; H J Deeg; T M Leonard; E D Thomas; R Storb
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

4.  Cyclosporin blood levels do correlate with clinical complications.

Authors:  E Irschik; H Tilg; D Niederwieser; G Gastl; C Huber; R Margreiter
Journal:  Lancet       Date:  1984-09-22       Impact factor: 79.321

5.  Differentiation between allograft rejection and cyclosporin nephrotoxicity in renal-transplant recipients.

Authors:  D H Taube; G H Neild; D G Williams; J S Cameron; B Hartley; C S Ogg; C J Rudge; K I Welsh
Journal:  Lancet       Date:  1985-07-27       Impact factor: 79.321

6.  Simplified liquid-chromotographic analysis for cyclosporin A, and comparison with radioimmunoassay.

Authors:  S G Carruthers; D J Freeman; J C Koegler; W Howson; P A Keown; A Laupacis; C R Stiller
Journal:  Clin Chem       Date:  1983-01       Impact factor: 8.327

Review 7.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

8.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981

9.  Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone.

Authors:  R K Sibley; J Rynasiewicz; R M Ferguson; D Fryd; D E Sutherland; R L Simmons; J S Najarian
Journal:  Surgery       Date:  1983-08       Impact factor: 3.982

  9 in total
  12 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

2.  Proceedings of the British Pharmacological Society. 12-14 September 1990, Belfast.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

3.  Prediction of acute graft rejection in renal transplantation: the utility of cyclosporine blood concentrations.

Authors:  J Grevel; K L Napoli; M S Welsh; N E Atkinson; B D Kahan
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

Review 4.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 5.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

6.  The influence of haematocrit on blood cyclosporin measurements in vivo.

Authors:  A Johnston; J T Marsden; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

7.  A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.

Authors:  A Lindholm; R Dahlqvist; G G Groth; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

8.  Monitoring of the free concentration of cyclosporine in plasma in man.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 9.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.